Theme: EMG/Neuromuscular
Susan Apkon, MD (she/her/hers)
Fishchahs Chair in Pediatric Rehabilitation
Childrens Hospital Colorado
Aurora, Colorado
Disclosed no relevant financial relationships.
Anne Stratton, MD
Associate Professor
Children's Hospital Colorado
Aurora, Colorado
Disclosed no relevant financial relationships.
Kathryn Mosher, MD
Pediatric Physiatrist, Director Neuromuscular Program
Akron Childrens Hospital
OH Copley, Ohio
Disclosed no relevant financial relationships.
Treatment options for newborns, children, and adults with spinal muscular atrophy has markedly changed over the last several years with 3 FDA approved drugs now available. These novel treatments are life saving and/or life changing in many who are treated. This session will briefly introduce the approved medications and outcomes in those treated. The primary focus of this session however will be a panel discussion by physiatrists and a neurologist who prescribe these medications to newborns, children, and adults with SMA. Real world cases will be used to highlight the complex decision making involved when providing options to a patient with spinal muscular atrophy. The panel will discuss issues including age of patient, type of spinal muscular atrophy, risk/benefit profiles, comorbidities that could limit options, and challenges with insurance approval. The learners will be given an opportunity to ask questions of the panel during the session to allow for a robust and engaging conversation.
Speaker: Susan D. Apkon, MD (she/her/hers) – Childrens Hospital Colorado
Speaker: Anne T. Stratton, MD – Children's Hospital Colorado
Speaker: Kathryn A. Mosher, MD – Akron Childrens Hospital
Speaker: Thomas Crawford, MD – n/a